Cerivastatin: Pharmacology of a novel synthetic and highly active HMG- CoA reductase inhibitor

Atherosclerosis

Volumn 135, Issue 1, 1997, Pages 119-130

  Bischoff, Hilmar ^a   Angerbauer, Rolf ^a   Bender, Joachim ^a   Bischoff, Erwin ^a   Faggiotto, Agostino ^b   Petzinna, Dieter ^a   Pfitzner, Jörg ^a   Porter, Michael C ^c   Schmidt, Delf ^a   Thomas, Günter ^a  

^a BAYER AG   (Germany)

^b Bayer SpA Italy   (Italy)

^c BAYER CORPORATION   (United States)

Author keywords

Atherosclerosis; Dogs; HMG CoA reductase inhibition; Rabbits; Rats; Tissue selectivity

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL STRAIN HEPG2; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT;

ADMINISTRATION, ORAL; ADRENAL GLANDS; ANIMALS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CELL LINE; DOGS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINE, SMALL; MALE; ORGAN SPECIFICITY; PYRIDINES; RABBITS; RATS; RATS, INBRED STRAINS; RATS, WISTAR; STEREOISOMERISM; TESTIS;

EID: 18844478213     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00188-3     Document Type: Article

References (31)

1. Neaton J.D., Wentworth D. MPH, for the multiple risk factor intervention trial research group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Intern Med. 152:1992;56-64.
2. National Cholesterol Education Program Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation. 89:1994;1329-1359.
3. Grundy S.M. Cholesterol and coronary heart disease. J Am Med Assoc. 264:1990;3053-3059.
4. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
5. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med. 320:1989;915-924.
6. Levine G.N., Keaney J.F., Vita J.A. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. New Engl J Med. 332:1995;512-521.
7. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med. 333:1995;1301-1307.
8. Lipid Research Program The lipid research clinics coronary prevention trial results I. Reduction in incidence of coronary heart disease, II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc. 251:1984;351-374.
9. The MARS Research Group, Blankenhorn D.H., Azen S.P., Kramsch D.M., Mack W.J., Cashin-Hemphill L., Hodis H.N., DeBoer L.W.V., Mahrer P.R., Masteller M.J., Vailas L.I., Alaupovic P., Hirsch L.J. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Ann Intern Med. 119:1993;969-976.
10. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study group (4S). Lancet. 334:1994;1383-1389.
11. Eno A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 33:1994;1569-1582.
12. Alberts A.W., Chen J., Kuron G., Hunt V., Huff J., Hoffmann C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monagham R., Currie S., Stapley E., Albers-Schonberg G., Hensens O., Hirshfield J., Hoogsteen K., Liesch J., Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA. 77:1980;3957-3961.
13. Tsujita Y., Kuroda M., Shimada Y., Tanzawa M., Kaneko I., Tanaka M., Masuda H., Turami C., Watanabe Y., Fujii S. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibitor of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 877:1986;50-60.
14. Kovanen P.T., Bilheimer D.W., Goldstein J.L., Jaramillo J.J., Brown M.S. Regulatory role of hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA. 78:1981;1194-1198.
15. Chao Y., Chen J.S., Hunt V.M., Kuron G.W., Karkas J.D., Liou R., Alberts A.W. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Eur J Clin Pharmacol. 40:1991;S11-14.
16. Corsini A., Maggi F.M., Catapano A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharm Res. 31:1995;9-27.
17. Krause B.R., Newton R.S. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis. 117:1995;237-244.
18. Beg J.H., Stonik J.A., Brewer H.P. Purification and characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase from chicken liver. FEBS Lett. 80:1977;123-129.
19. Parker T.S., McNamara D.J., Brown C., Garigan O., Kolb R., Batwin H., Ahrens E.H. Jr. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA. 79:1982;3037-3041.
20. Duncan I.W., Culbreth P.H., Burtis C.A. Determination of free total, and esterified cholesterol by high-performance liquid chromatography. J Chromatogr. 162:1979;281-292.
21. Schmitz G., Assmann G. A quantitative densitometric method for the rapid separation and quantitation of the major tissue and lipoprotein lipids by high-performance thin-layer chromatography. J. Chromatogr. 307:1984;65-79.
22. Bartmann W., Beck G., Granzer E., Jendralla H., Krekjarto B.v., Wess G. Convenient two-step stereospecific hydroxy-substitution with retention in β-hydroxy-lactones. Tetrahedron Lett. 27:1986;4709-4712.
23. Ness G.C., Eales S.J., Pendleten L.C., Smith M. Activation of rat liver microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase by NADPH. J Biol Chem. 260:1985;12391-12393.
24. Ness R.A., Gould R.G. Prevention of cold inactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by NADPH. Biochem Biophys Acta. 388:1975;254-259.
25. Skrikantaiah M.V., Tormanen C.D., Redd W.L., Hardgrave J.E., Scallen T.J. Purification of 3-hydroxy-3-methylglutaryl coenzyme A reductase by affinity chromatography on blue dextran/sepharose 4B. J Biol Chem. 252:1977;6145-6150.
26. Corsini A., Fumagalli R., Paoletti R., Bernini F. Preclinical studies of fluvastatin. Drugs Today. 32:1996;19-38.
27. Faust J.R., Goldstein J.L., Brown M.S. Receptor-mediated uptake of low density lipoprotein and utilization of its cholesterol for steroid synthesis in cultured mouse adrenal cells. J Biol Chem. 252:1977;4861.
28. Kovanen P.T., Basu S.K., Goldstein J.L., Brown M.S. Low density lipoprotein receptors in bovine adrenal cortex. II. Low density lipoprotein binding to membranes prepared from fresh tissue. Endocrinology. 104:1979;610.
29. Steinke W., Yamashita S., Tabei M., Ahr H.J., Beckermann B., Domdey-Bette A., Göller G., Schwarz T., Siefert H.M. Cerivastatin, a new inhibitor of HMG-CoA reductase: pharmacokinetics in rats and dogs. Jpn Pharmacol Ther. 24(Suppl. 9):1996;S1217-S1237.
30. Saunders K.D., Cates J.A., Abedin M.Z., Rege S., Festekdjian S.F., Howard W., Roslyn J.J. Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog. Ann Surg. 214:1991;149-154.
31. The Cerivastatin Study Group, Stein E., Sprecher D., Allenby K.S., Tosiello R.L., Whalen E., Ripa S.R. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther. 2:1997;7-16.